Stelia Ntika, Camilla Krizhanovskii, L. Tracy, S. Bringman, P. Lundquist
{"title":"Improved Beta-Cell Function and Altered Plasma Levels of GLP-1 During OMTT and Fasting Following Bariatric Surgery in Women with NGT","authors":"Stelia Ntika, Camilla Krizhanovskii, L. Tracy, S. Bringman, P. Lundquist","doi":"10.31031/IOD.2021.05.000604","DOIUrl":null,"url":null,"abstract":"Context: Bariatric surgery can be considered metabolic surgery, with important weight loss-independent effects on metabolism. Altered secretion of the intestinal hormone Glucagon-Like Peptide-1 (GLP-1) may be an important factor in the metabolic success of bariatric surgery. GLP-1 is an important regulator of glucose metabolism, reducing glycemia by regulating insulin and glucagon secretion, slowing gastric emptying, and lowering the desire for food intake. A potentiating effect of bariatric surgery on postprandial GLP-1 secretion is well documented and contributes to the increased insulin secretion and sensitivity that precedes weight loss. However, studies on patients with Normal Glucose Tolerance (NGT) are relatively few, and a clear consensus is still lacking in terms of potential effects of bariatric surgery on fasting GLP-1 levels in obese subjects with NGT. To investigate fasting and postprandial levels of GLP-1 in obese women with NGT before and after bariatric surgery. Design: Plasma GLP-1 was quantified at fasting and during an Oral Meal Tolerance Test (OMTT) in female patients with NGT subjected to Vertical Sleeve Gastrectomy (VSG) or Roux-en-Y Gastric Bypass (RYGB), preoperatively and 3 months postoperatively. Insulin resistance was quantified using HOMA-IR, and beta cell function using the Oral Disposition Index (DIo). Setting: This study was performed Patients and participants: Eleven female patients aged 18-65 years with a BMI≥40 kg/m 2 and NGT were included. Exclusion criteria were T2D (based on the criteria of the American Diabetes Association (ADA) (2014)), prior GLP-1 based therapy or insulin therapy, and history of substance abuse (drugs or alcohol). Main outcome measures: Outcome measures were fasting and OMTT plasma levels of insulin and GLP-1. Results: Fasting GLP-1 levels were decreased 3 months postoperatively compared to baseline (12.3±1.5 vs. 20.1±3.4 pmol/L, p=0.05). Meal-stimulated GLP-1 secretion was significantly increased 3 months postoperatively in association with increased insulin sensitivity and enhanced beta cell function. Conclusion: Bariatric surgery reduces fasting plasma GLP-1 levels, while significantly increasing meal-stimulated plasma GLP-1 levels, in obese women with NGT.","PeriodicalId":170669,"journal":{"name":"Interventions in Obesity & Diabetes","volume":"87 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventions in Obesity & Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/IOD.2021.05.000604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Context: Bariatric surgery can be considered metabolic surgery, with important weight loss-independent effects on metabolism. Altered secretion of the intestinal hormone Glucagon-Like Peptide-1 (GLP-1) may be an important factor in the metabolic success of bariatric surgery. GLP-1 is an important regulator of glucose metabolism, reducing glycemia by regulating insulin and glucagon secretion, slowing gastric emptying, and lowering the desire for food intake. A potentiating effect of bariatric surgery on postprandial GLP-1 secretion is well documented and contributes to the increased insulin secretion and sensitivity that precedes weight loss. However, studies on patients with Normal Glucose Tolerance (NGT) are relatively few, and a clear consensus is still lacking in terms of potential effects of bariatric surgery on fasting GLP-1 levels in obese subjects with NGT. To investigate fasting and postprandial levels of GLP-1 in obese women with NGT before and after bariatric surgery. Design: Plasma GLP-1 was quantified at fasting and during an Oral Meal Tolerance Test (OMTT) in female patients with NGT subjected to Vertical Sleeve Gastrectomy (VSG) or Roux-en-Y Gastric Bypass (RYGB), preoperatively and 3 months postoperatively. Insulin resistance was quantified using HOMA-IR, and beta cell function using the Oral Disposition Index (DIo). Setting: This study was performed Patients and participants: Eleven female patients aged 18-65 years with a BMI≥40 kg/m 2 and NGT were included. Exclusion criteria were T2D (based on the criteria of the American Diabetes Association (ADA) (2014)), prior GLP-1 based therapy or insulin therapy, and history of substance abuse (drugs or alcohol). Main outcome measures: Outcome measures were fasting and OMTT plasma levels of insulin and GLP-1. Results: Fasting GLP-1 levels were decreased 3 months postoperatively compared to baseline (12.3±1.5 vs. 20.1±3.4 pmol/L, p=0.05). Meal-stimulated GLP-1 secretion was significantly increased 3 months postoperatively in association with increased insulin sensitivity and enhanced beta cell function. Conclusion: Bariatric surgery reduces fasting plasma GLP-1 levels, while significantly increasing meal-stimulated plasma GLP-1 levels, in obese women with NGT.